Raphael Pharmaceutical Stock Current Ratio
| RAPH Stock | 0.26 0.00 0.00% |
Raphael Pharmaceutical fundamentals help investors to digest information that contributes to Raphael Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Raphael OTC Stock. The fundamental analysis module provides a way to measure Raphael Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Raphael Pharmaceutical otc stock.
Raphael |
Raphael Pharmaceutical OTC Stock Current Ratio Analysis
Raphael Pharmaceutical's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Raphael Pharmaceutical has a Current Ratio of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Ratio (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Raphael Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.Raphael Pharmaceutical is currently under evaluation in current ratio category among its peers.
Raphael Fundamentals
| Return On Asset | -19.04 | |||
| Shares Outstanding | 15.62 M | |||
| EBITDA | (1.63 B) | |||
| Net Income | (1.62 B) | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.42 M) | |||
| Market Capitalization | 17.19 M | |||
| Total Asset | 422 K | |||
| Net Asset | 422 K |
About Raphael Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.